Nilvadipine - Archer Pharmaceuticals

Drug Profile

Nilvadipine - Archer Pharmaceuticals

Alternative Names: ARC 029

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Archer Pharmaceuticals
  • Class Antidementias; Antihypertensives; Dihydropyridines; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 10 Feb 2016 Nilvadipine is still in phase III trial for Alzheimer's Disease in France, Germany, Greece, Hungary, Ireland, Italy, Sweden, United Kingdom and the Netherlands (NCT02017340)
  • 30 Jan 2014 No development reported - Phase-I for Alzheimer's disease in USA (PO)
  • 31 Oct 2012 Phase-III clinical trials in Alzheimer's disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top